Unicycive Therapeutics is a US-based biotech company that focuses on developing innovative therapies for kidney diseases. The company's flagship products include Renazorb and UNI 494 which target hyperphosphatemia in chronic kidney disease patients and acute kidney injury, respectively. Established in 2016, the company is headquartered in Los Altos, California.